Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924272 · ClinicalTrials.gov registry record · Phase 2
Ixazomib Rollover Study
A Phase 2 study of Multiple Myeloma and Lymphoma, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 20
- Study locations
NCT02924272: Completed Phase 2 study of Multiple Myeloma and Lymphoma, sponsored by Takeda.
NCT02924272 is a Phase 2 study of Multiple Myeloma and Lymphoma that has completed, run by Takeda. The registered enrollment target is 32 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02924272, a Phase 2 study of Multiple Myeloma and Lymphoma, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
Primary Outcome
An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. An SAE is any untowar
Conditions Studied
Interventions
- DRUG Ixazomib
Study Locations (20)
Other
- UZ Leuven - Leuven
- 1st Affiliated Hospital of Zhejiang University - Hangzhou
- Shanghai Chang Zheng Hospital - Shanghai
- University of Athens Medical School - Regional General Hospital Alexandra - Athens
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi - Lodz
- Centrum Onkologii Ziemi Lubelskiej - Lublin
- MTZ Clinical Research Sp z o o - Warsaw
- National University Hospital - Singapore
Ontario
- Princess Margaret Cancer Centre - Toronto
- University Health Network - Toronto
Beijing Municipality
- Peking University Third Hospital - Beijing
- Peking Union Medical College Hospital - Beijing
Tokyo
- Tokyo Metropolitan Komagome Hospital - Bunkyo-Ku
- Japanese Red Cross Medical Center - Shibuya-Ku
Georgia
- Emory University - Atlanta
Kentucky
- Appalachian Regional Healthcare - Hazard
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2024-07-03 |
| Phase | Phase 2 |
What the finished NCT02924272 record still lists
NCT02924272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Ixazomib is the first listed.
NCT02924272 names 20 study sites across 10 states, led by Other, Ontario, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT02924272 about?
NCT02924272 is a clinical study titled "Ixazomib Rollover Study". The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
What is the current status of trial NCT02924272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2016-12-16. Estimated completion is 2024-07-03.
What conditions does trial NCT02924272 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Amyloidosis.
What interventions are being tested in trial NCT02924272?
The interventions under investigation include: Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02924272?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02924272 being conducted?
This trial has 20 study locations across Georgia, Kentucky, Massachusetts, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02924272's enrollment target sits among peer trials
32 324th of 438 higher than 104 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI